Details of the Drug

General Information of Drug (ID: DMYD37G)

Drug Name
CV8102
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [1]
Squamous cell carcinoma 2B60-2D01 Phase 1 [1]
Cross-matching ID
TTD ID
DVU2H8
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinoic acid-inducible gene-1 (RIG-1) TTVB0O3 DDX58_HUMAN Agonist [2]
Toll-like receptor 7 (TLR7) TTRJ1K4 TLR7_HUMAN Agonist [2]
Toll-like receptor 8 (TLR8) TT8CWFK TLR8_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 7 (TLR7) DTT TLR7 3.32E-25 0.44 0.88
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03291002) Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of CureVac.